eISSN 2288-3657
pISSN 2288-3649
pISSN 2288-3649
Baseline characteristics of the 43 patients with metastatic CRC
| Characteristic | Total patients (n = 43) |
|---|---|
| Age (yr) | |
| Median (range) | 63 (21-79) |
| ≥ 63 | 24 (55.8) |
| < 63 | 19 (44.2) |
| ECOG PS score | |
| 0-1 | 23 (53.5) |
| 2 | 20 (46.5) |
| Sex | |
| Male | 27 (62.8) |
| Female | 16 (37.2) |
| Pathological stage | |
| IIIb | 4 (9.3) |
| IV | 39 (90.3) |
| Primary tumor site | |
| Right | 18 (41.9) |
| Left or rectum | 25 (58.1) |
| Previous systemic treatment | |
| Second line | 11 (25.6) |
| Third line and above | 32 (74,4) |
| Surgical treatment history | |
| Yes | 27 (62.8) |
| No | 16 (37.2) |
| MMR status | |
| dMMR | 4 (9.3) |
| pMMR | 24 (55.8) |
| Unknown | 15 (34.9) |
| Number of metastases sites | |
| ≤ 3 | 24 (55.8) |
| > 3 | 19 (44.2) |
| Liver metastases | |
| Yes | 31 (72.1) |
| No | 12 (27.9) |
| Initial dosage of apatinib (mg) | |
| 250 | 26 (60.5) |
| 500 | 17 (39.5) |
| PD-1 blockades | |
| Camrelizumab | 23 (53.5) |
| Sintilimab | 14 (32.6) |
| Pembrolizumab | 6 (13.9) |
Values are presented as number (%) or otherwise indicated. CRC, colorectal cancer; ECOG, Eastern Cooperative Oncology Group; PS, performance status; MMR, mismatch repair; dMMR, mismatch repair-deficient; pMMR, proficient mismatch repair; PD-1, programmed cell death protein 1.
J Cancer Prev 2023;28:106~114 https://doi.org/10.15430/JCP.2023.28.3.106
© J Cancer Prev
© Korean Society of Cancer Prevention. / Powered by INFOrang Co., Ltd